Orforglipron vs Tesamorelin
Extensively Studied vs FDA Approved
monitor Mechanism-based · 50% Both Orforglipron and Tesamorelin promote fat breakdown. While additive fat loss is possible, excessive lipolysis can cause rapid free fatty acid elevation and cardiac strain. Monitor heart rate and adjust doses gradually.
Molecular Data
Orforglipron Tesamorelin
Weight 882.974 Da 5,135.9 Da
Half-life 25-68 hours 26-38 minutes
Chain Non-peptide small molecule 44 amino acids
Type Small-molecule GLP-1R agonist GHRH analog
Key Benefits
Orforglipron
01 Significant weight loss (up to 12.4% at 72 weeks)
02 Robust diabetes control (HbA1c reduction 1.3-1.6%)
03 Once-daily oral tablet format
04 No refrigeration or food restrictions required
05 Reduced cardiovascular risk markers
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
Orforglipron
Start 3-6mg daily, titrate up to 12-36mg based on response / Once daily oral tablet
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
Orforglipron
Diarrhea (more prevalent than with injectable GLP-1s)
Nausea (typically improves after first month)
Appetite reduction
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy and breastfeeding
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
Orforglipron Tesamorelin
Status Extensively Studied FDA Approved
References 4 studies 5 studies
Latest — June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.